Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07030712 · ClinicalTrials.gov registry record · Phase 1
A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)
A Phase 1 study of Metastatic Neoplasm, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 67
- Enrollment target
- 5
- Study locations
NCT07030712: Recruiting Phase 1 study of Metastatic Neoplasm, sponsored by Merck Sharp & Dohme.
NCT07030712 is a Phase 1 study of Metastatic Neoplasm that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 67 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (12% higher). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07030712, a Phase 1 study of Metastatic Neoplasm, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 67 participants
- Enrollment target
- 5
- Study locations
Study Summary
MK-8294, the study medicine, is a type of targeted therapy designed to treat certain solid tumors. The main goals of this study are to learn about the safety of MK-8294 and if people can tolerate it and find the highest dose level of MK-8294 that people can tolerate.
Primary Outcome
DLT is defined as any drug-related adverse event (AE) observed during the DLT evaluation period (up to 35 days) that results in a change to a given dose or a delay in initiating the next treatment and reported as the number of participants experiencing a DLT.
Conditions Studied
Interventions
- DRUG MK-8294
Study Locations (5)
Other
- Rambam Health Care Campus ( Site 0201) - Haifa
- Sheba Medical Center ( Site 0200) - Ramat Gan
Illinois
- Northwestern University ( Site 0101) - Chicago
Gelderland
- Radboudumc ( Site 0301) - Nijmegen
North Holland
- Nederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 0300) - Amsterdam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2025-07-23 |
| Est. Completion | 2027-08-23 |
| Phase | Phase 1 |
What NCT07030712 shows while recruiting
NCT07030712 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 67 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (12% higher).
The record links to 1 condition, with Metastatic Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which MK-8294 is the first listed.
NCT07030712 lists 5 locations in 4 states (Other, Illinois, Gelderland).
Frequently Asked Questions
What is clinical trial NCT07030712 about?
NCT07030712 is a clinical study titled "A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)". MK-8294, the study medicine, is a type of targeted therapy designed to treat certain solid tumors. The main goals of this study are to learn about the safety of MK-8294 and if people can tolerate it and find the highest dose level of MK-8294 that people can tolerate.
What is the current status of trial NCT07030712?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 67 participants. The study started on 2025-07-23. Estimated completion is 2027-08-23.
What conditions does trial NCT07030712 study?
This clinical trial studies the following conditions: Metastatic Neoplasm.
What interventions are being tested in trial NCT07030712?
The interventions under investigation include: MK-8294 (DRUG).
Who is sponsoring clinical trial NCT07030712?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07030712 being conducted?
This trial has 5 study locations across Illinois, Gelderland, North Holland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07030712's enrollment target sits among peer trials
67 782nd of 2000 higher than 1,215 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03213002 · 67 participants · Phase 1
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
- NCT04115163 · 67 participants · Phase 2
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
- NCT04315324 · 67 participants · Phase 1
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
- NCT04532424 · 67 participants · NA
Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI